File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Efficacy of Combination Chemotherapy with Irinotecan (CPT-11) plus Capecitabine in Patients with Metastatic or Advanced Colorectal Carcinoma - a Dual-centre Phase II Study: the MAC-6
  • Basic View
  • Metadata View
  • XML View
TitleEfficacy of Combination Chemotherapy with Irinotecan (CPT-11) plus Capecitabine in Patients with Metastatic or Advanced Colorectal Carcinoma - a Dual-centre Phase II Study: the MAC-6
 
AuthorsChoi, CKK2
Chan, RTT2
Tung, SY1
Lui, L2
Siu, S2
Au, GKH2
Ho, JWC2
Law, WL2
 
KeywordsCapecitabine
CPT-11
irinotecan
metastatic colorectal cancer
 
Issue Date2008
 
PublisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/clon
 
CitationClinical Oncology, 2008, v. 20 n. 2, p. 168-175 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.clon.2007.11.008
 
AbstractAims: A phase II trial was initiated to evaluate the efficacy and toxicity of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic colorectal cancer. Patients and methods: Patients received a combination of CPT-11 plus capecitabine. CPT-11 was infused intravenously on day 1 every 2 weeks and oral capecitabine was taken twice daily for 5 days every 7 days. Efficacy and toxicities were assessed. Results: Between 2004 and 2005, 43 patients were enrolled. The overall response rate was 51.35%. With a median follow-up of 13 months, the median time to progression was 10 months (95% confidence interval 7.6-12.3 months); the median survival was 15 months (95% confidence interval 13.9-16.9 months). The most common grade 3 haematological and non-haematological toxicities were neutropenia (5.4%), diarrhoea (8.1%) and hand-foot syndrome (2.7%). Conclusions: CPT-11 plus capecitabine with a 14 day cycle showed a comparable response with international phase II data with a 3 weekly regimen and was well tolerated as a first-line palliative chemotherapy in patients with metastatic colorectal cancer. The data should be interpreted with caution due to the limited sample size and should be further confirmed by a phase III randomised trial. © 2007 The Royal College of Radiologists.
 
ISSN0936-6555
2013 Impact Factor: 2.826
 
DOIhttp://dx.doi.org/10.1016/j.clon.2007.11.008
 
ISI Accession Number IDWOS:000254160500009
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorChoi, CKK
 
dc.contributor.authorChan, RTT
 
dc.contributor.authorTung, SY
 
dc.contributor.authorLui, L
 
dc.contributor.authorSiu, S
 
dc.contributor.authorAu, GKH
 
dc.contributor.authorHo, JWC
 
dc.contributor.authorLaw, WL
 
dc.date.accessioned2010-09-06T08:42:01Z
 
dc.date.available2010-09-06T08:42:01Z
 
dc.date.issued2008
 
dc.description.abstractAims: A phase II trial was initiated to evaluate the efficacy and toxicity of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic colorectal cancer. Patients and methods: Patients received a combination of CPT-11 plus capecitabine. CPT-11 was infused intravenously on day 1 every 2 weeks and oral capecitabine was taken twice daily for 5 days every 7 days. Efficacy and toxicities were assessed. Results: Between 2004 and 2005, 43 patients were enrolled. The overall response rate was 51.35%. With a median follow-up of 13 months, the median time to progression was 10 months (95% confidence interval 7.6-12.3 months); the median survival was 15 months (95% confidence interval 13.9-16.9 months). The most common grade 3 haematological and non-haematological toxicities were neutropenia (5.4%), diarrhoea (8.1%) and hand-foot syndrome (2.7%). Conclusions: CPT-11 plus capecitabine with a 14 day cycle showed a comparable response with international phase II data with a 3 weekly regimen and was well tolerated as a first-line palliative chemotherapy in patients with metastatic colorectal cancer. The data should be interpreted with caution due to the limited sample size and should be further confirmed by a phase III randomised trial. © 2007 The Royal College of Radiologists.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationClinical Oncology, 2008, v. 20 n. 2, p. 168-175 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.clon.2007.11.008
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.clon.2007.11.008
 
dc.identifier.epage175
 
dc.identifier.hkuros141229
 
dc.identifier.isiWOS:000254160500009
 
dc.identifier.issn0936-6555
2013 Impact Factor: 2.826
 
dc.identifier.issue2
 
dc.identifier.openurl
 
dc.identifier.pmid18155454
 
dc.identifier.scopuseid_2-s2.0-39049165189
 
dc.identifier.spage168
 
dc.identifier.urihttp://hdl.handle.net/10722/83520
 
dc.identifier.volume20
 
dc.languageeng
 
dc.publisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/clon
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofClinical Oncology
 
dc.relation.referencesReferences in Scopus
 
dc.subjectCapecitabine
 
dc.subjectCPT-11
 
dc.subjectirinotecan
 
dc.subjectmetastatic colorectal cancer
 
dc.titleEfficacy of Combination Chemotherapy with Irinotecan (CPT-11) plus Capecitabine in Patients with Metastatic or Advanced Colorectal Carcinoma - a Dual-centre Phase II Study: the MAC-6
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Choi, CKK</contributor.author>
<contributor.author>Chan, RTT</contributor.author>
<contributor.author>Tung, SY</contributor.author>
<contributor.author>Lui, L</contributor.author>
<contributor.author>Siu, S</contributor.author>
<contributor.author>Au, GKH</contributor.author>
<contributor.author>Ho, JWC</contributor.author>
<contributor.author>Law, WL</contributor.author>
<date.accessioned>2010-09-06T08:42:01Z</date.accessioned>
<date.available>2010-09-06T08:42:01Z</date.available>
<date.issued>2008</date.issued>
<identifier.citation>Clinical Oncology, 2008, v. 20 n. 2, p. 168-175</identifier.citation>
<identifier.issn>0936-6555</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/83520</identifier.uri>
<description.abstract>Aims: A phase II trial was initiated to evaluate the efficacy and toxicity of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic colorectal cancer. Patients and methods: Patients received a combination of CPT-11 plus capecitabine. CPT-11 was infused intravenously on day 1 every 2 weeks and oral capecitabine was taken twice daily for 5 days every 7 days. Efficacy and toxicities were assessed. Results: Between 2004 and 2005, 43 patients were enrolled. The overall response rate was 51.35%. With a median follow-up of 13 months, the median time to progression was 10 months (95% confidence interval 7.6-12.3 months); the median survival was 15 months (95% confidence interval 13.9-16.9 months). The most common grade 3 haematological and non-haematological toxicities were neutropenia (5.4%), diarrhoea (8.1%) and hand-foot syndrome (2.7%). Conclusions: CPT-11 plus capecitabine with a 14 day cycle showed a comparable response with international phase II data with a 3 weekly regimen and was well tolerated as a first-line palliative chemotherapy in patients with metastatic colorectal cancer. The data should be interpreted with caution due to the limited sample size and should be further confirmed by a phase III randomised trial. &#169; 2007 The Royal College of Radiologists.</description.abstract>
<language>eng</language>
<publisher>WB Saunders Co Ltd. The Journal&apos;s web site is located at http://www.elsevier.com/locate/clon</publisher>
<relation.ispartof>Clinical Oncology</relation.ispartof>
<subject>Capecitabine</subject>
<subject>CPT-11</subject>
<subject>irinotecan</subject>
<subject>metastatic colorectal cancer</subject>
<title>Efficacy of Combination Chemotherapy with Irinotecan (CPT-11) plus Capecitabine in Patients with Metastatic or Advanced Colorectal Carcinoma - a Dual-centre Phase II Study: the MAC-6</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0936-6555&amp;volume=20&amp;issue=2&amp;spage=168&amp;epage=175&amp;date=2008&amp;atitle=Efficacy+of+combination+chemotherapy+with+irinotecan+(CPT-11)+plus+capecitabine+in+patients+with+metastatic+or+advanced+colorectal+carcinoma+-+a+dual-centre+phase+II+study:+the+MAC-6</identifier.openurl>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.clon.2007.11.008</identifier.doi>
<identifier.pmid>18155454</identifier.pmid>
<identifier.scopus>eid_2-s2.0-39049165189</identifier.scopus>
<identifier.hkuros>141229</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-39049165189&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>20</identifier.volume>
<identifier.issue>2</identifier.issue>
<identifier.spage>168</identifier.spage>
<identifier.epage>175</identifier.epage>
<identifier.isi>WOS:000254160500009</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
</item>
Author Affiliations
  1. Tuen Mun Hospital
  2. Queen Mary Hospital Hong Kong